PTPRJ Antibody

1. PTPRJ variant of uncertain significance in candidate gene was identified in Familial Mitral Valve Prolapse. PMID:29762926
2. Short variant of the receptor protein phosphatase PTPRJ generated by an alternative splicing promotes angiogenesis in HUVEC cells and tumor angiogenesis. PMID:28052032
3. study reveals the crucial role of miR-155/PTPRJ/AKT axis in proliferation and migration of colorectal cancer cells and suggests a therapeutic potential of PTPRJ. PMID:28316102
4. Authors demonstrate that mtp53 prevents the COP1/DET1 complex from ubiquitinating ETS2 and thereby marking it for destruction. Authors show that mtp53 destabilizes DET1 and also disrupts the DET1/ETS2 complex thereby preventing ETS2 degradation. PMID:26871468
5. These data support that PTPN22 1858C/T, PTPRJ 2965C/G and 1176 A/C polymorphisms and ACP1 A, B and C alleles are not associated with a higher risk of immune thrombocytopenia P in adults. PMID:27309885
6. Loss of PTPRJ expression may predict an aggressive clinical course in ESCC patients. PMID:26694178
7. The strongest association with frailty was observed in the Protein Tyrosine Phosphatase, Receptor type, J (PTPRJ) (rs1566729, P = 0.001372, beta = 0.09397) gene. PMID:26248682
8. the combination of CD200 and CD148 may have a potential differential diagnostic value in leukemic B-CLPDs, especially between CLL and MCL. PMID:25791119
9. These results demonstrated Ptprj as a physiological enzyme that attenuates insulin signalling in vivo, and indicate that an inhibitor of Ptprj may be an insulin-sensitizing agent. PMID:26063811
10. CD148 tyrosine phosphatase promotes e-cadherin cell adhesion. PMID:25386896
11. The studies suggest induction of MMP-9 expression promoted by DEP-1 deficiency. PMID:25672645
12. Moderate expression of DEP-1 was associated with the increased relapse. PMID:25772245
13. C33A cells lacking PTPRJ had increased cell viability, growth, migration, G1-S transition, and 5-FU resistance. PTPRJ negatively regulated the JAK1/STAT3 pathway by decreasing phosphorylation levels of JAK1 and STAT3 and expression of downstream factors. PMID:25634668
14. The expression profiles of DEP1 and B2MG correlate with increased cell senescence and survival in breast cancer. PMID:25412306
15. Phosphorylation of T1318 is part of a regulatory mechanism that channels the activity of DEP-1 towards Src to allow its optimal activation and the promotion of endothelial cell permeability. PMID:24583284
16. Data indicate that CD148 is upregulated in macrophages and T cells in rheumatoid arthritis (RA) samples, and its activity is enhanced by treatment with tumour necrosis factor alpha (TNFalpha), and reduced by synovial fluid or oxidising conditions. PMID:24016860
17. our data support the notion of DEP-1 as positive functional regulator in vascular cerebral arteriogenesis, involving differential PDGF-B gene expression. PMID:24027763
18. FLT3 is a bona fide substrate of DEP-1 and that interaction occurs mainly via an enzyme-substrate complex formation triggered by FLT3 ligand stimulation. PMID:23650535
19. haplotypes in PTPRJ gene may play a role in susceptibility to Non-Hodgkin's lymphoma, by affecting activation of PTPRJ in these B-cell lymphomas. PMID:23341091
20. Data indicate that miR-328 regulated PTPRJ expression, and suggest that the interaction of miR-328 with PTPRJ is responsible for miR-328-dependent increase of epithelial cell proliferation. PMID:22564856
21. These data indicate that PTPRJ may regulate differentiation of normal mammary epithelia and that dysregulation of protein localisation may be associated with tumorigenesis. PMID:22815804
22. CD148 polymorphisms affect platelet activation and probably exert a protective effect on the risk of Heparin-induced thrombocytopenia in patients with antibodies to PF4/Heparin complexes. PMID:22677127
23. DEP-1 oxidation is a novel event contributing to cell transformation by FLT3 ITD. PMID:22438257
24. These findings provide evidence that CD148 functions as a receptor for TSP1 and mediates its inhibition of cell growth. PMID:22308318
25. Here the protein tyrosine phosphatase receptor CD148 is shown to be a key intermediary in cell adhesion to S2ED, with downstream beta1 integrin-mediated adhesion and cytoskeletal organization PMID:21813734
26. We propose that positive regulation of adhesion signaling by DEP-1 is involved in inhibition of meningioma cell motility, and possibly tumor invasiveness. PMID:21091576
27. differential effects of CD148 in T cells and other leukocyte subsets PMID:21543337
28. That DEP-1 plays a biologic role in angiogenic endothelial cell behavior was demonstrated in endothelial cell migration, proliferation, and capillary-like tube formation assays in vitro PMID:21304107
29. DEP-1 is negatively regulating FLT3 signaling activity and that its loss may contribute to but is not sufficient for leukemogenic cell transformation. PMID:21262971
30. Therefore, the results reported here show that the homozygous genotype for Asp872 of PTPRJ is associated with an increased risk to develop papillary thyroid carcinoma. PMID:20823296
31. PTPRJ is a candidate colorectal cancer susceptibility gene PMID:21036128
32. DEP-1 is a tumor suppressor that dephosphorylates and thereby stabilizes EGFR by hampering its ability to associate with the CBL-GRB2 ubiquitin ligase complex. PMID:19836242
33. PTPRJ SNPs were found to influence susceptibility to a wide spectrum of cancers. PMID:19672627
34. This protein is frequently deleted in human breast cancers. PMID:12089527
35. CD148 and CD27 are expressed in a wide range of B cell non-Hodgkin's lymphomas and do not serve to distinguish between neoplastic cells of naive and memory B cell derivation PMID:12685844
36. DEP-1 is a negative regulator of cell proliferation, cell-substratum contacts, motility and chemotaxis in fibroblasts PMID:14709717
37. propose that the expression and activation of DEP-1/PTPeta is required for somatostatin inhibition of glioma proliferation PMID:15123617
38. A candidate tumor suppressor gene because its expression was blocked in rat and human thyroid transformed cells, and its restoration reverted their neoplastic phenotype. PMID:15231692
39. genotypic profile of PTPRJ affects susceptibility to thyroid carcinomas, loss involved in thyroid carcinogenesis PMID:15378013
40. single nucleotide polymorphisms in protein tyrosine phosphatase receptor type J is associated with breast cancer PMID:16000320
41. Male, dizygotic twins were diagnosed with sensori-neural deafness at ages 5 and 21 months and later developed hypothyroidism at ages 24 and 28 months, respectively. Analysis for anti-DEP-1/CD148 autoantibodies described in Cogan syndrome proved positive. PMID:16582570
42. Chemoprotective nutrients elevated transcription of endogenous DEP-1 mRNA & expression of DEP-1 protein. Upregulation of DEP-1 expression & inhibition of cell growth & migration may be a previously unrecognized mechanism of chemoprevention by nutrients. PMID:16682945
43. These results demonstrate that CD148 may interact with and dephosphorylate p85 when it is phosphorylated and modulate the magnitude of phosphoinositide 3-kinase activity. PMID:18348712
44. The translation of the region between AUG(191) and AUG(356) inhibits the overall expression of PTPRJ mRNA. PMID:18603590
45. No significant evidence for the A1176C allele of PTPRJ or previously described haplotypes of tagSNPs in PTPRJ on CRC risk. PMID:18843023
46. DEP-1 is a positive regulator of VEGF-mediated Src and Akt activation and endothelial cell survival. PMID:18936167
47. The intact structure of the eighth fibronectin domain of PTPRJ is critical for its localization in plasma membrane and biological function. PMID:19122201
48. DEP-1 can modify the phosphorylation state of tight junction proteins and play a role in regulating permeability. PMID:19332538
49. CD148 may have a role in mantle cell lymphoma PMID:19413345
50. In this paper, frequent deletion of PTPRJ is shown in human colon, lung, and breast cancers. PMID:12089527

Show More

Hide All

HGNC: 9673

UNIGENE: Hs.318547

KEGG: hsa:5795

STRING: 9606.ENSP00000400010

OMIM: 600925